Study sheds light on H1N1 origins

The new H1N1 virus is only distantly related to its nearest relatives, suggesting that its genes may have been circulating undetected in pig populations for some time, according to new research published online by the journal Science. Scientists also confirm the novel status of the virus, noting that it contains a combination of gene segments that has never been reported before.

"This study reinforces the fact that swine are an important reservoir of influenza viruses with the potential to cause significant respiratory outbreaks or even a possible pandemic in humans, and the results of the study show the global need for more systemic surveillance of influenza viruses in pigs," commented Dr Nancy Cox, one of the authors of the paper and Director of the Influenza Division at the Centers for Disease Control and Prevention (CDC) in the US.

The study was partly supported by the EU through the EMPERIE (European management platform for emerging and re-emerging infectious disease entities) project, which is funded under the Seventh Framework Programme (FP7).

The researchers arrived at their conclusions by sequencing the genomes of over 70 samples of the H1N1 virus, most of which were taken from patients in Mexico and the US.

"From our analysis, we have confirmed that the novel H1N1 virus likely originated from pigs," said Dr Cox, adding that the new virus is very different from human H1N1 viruses, which indicates that "seasonal influenza H1 vaccines may not protect people from infection with this novel virus."

With the help of the samples, the researchers were able to piece together the history of the virus. Six of the eight gene segments studied came from a known strain of swine flu that has been circulating in North America and Asia since 1998. The remaining two segments come from Eurasian swine virus strains that have never been detected outside Eurasia until now. This combination of gene segments has never been seen before.

The samples also turned out to be extremely similar to one another, indicating that the virus crossed into humans just once. Alternatively, very similar viruses may have crossed into humans a number of times.

"While our analysis shows that all gene segments are derived from swine influenza viruses, at this time we do not know if the virus entered the human population directly from swine or via an intermediate host, nor do we know for certain the exact host that the viruses might previously have circulated in to obtain its current properties," Dr Cox pointed out.

She added that veterinary researchers around the world are now delving into their freezers to see if they have samples from pigs or other animals that could shed new light on the emergence of the new virus.

According to Dr Cox, the fact that the viruses are similar "makes our job of coming up with a reference candidate vaccine virus much, much easier."

According to the latest figures from the World Health Organization (WHO), a total of 12,954 cases (including 92 deaths) of H1N1 influenza have been officially diagnosed across 46 countries worldwide. Most of these cases are in the US and Mexico, which have so far reported 6,764 and 4,174 cases respectively.

For further information, please visit:

Copyright ©European Communities, 2009
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Novartis receives FDA approval for Mayzent® (sipon…

Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple scl...

Compound that kills drug-resistant fungi is isolat…

Antimicrobial and antifungal resistance, which describe the ability of bacteria and other pathogens to resist the effects of drugs to which they were once sensitive, is a...

First bacterial genome created entirely with a com…

All the genome sequences of organisms known throughout the world are stored in a database belonging to the National Center for Biotechnology Information in the United Sta...

Liver, colon cancer cells thwarted by compounds de…

The plant that adds flavor, color and bitterness to beer also produces a primary compound that thwarts cancer cells, and two important derivatives of the compound do as w...

Clinical trial finds therapy to be well-tolerated …

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated...

Immune cells fighting blood cancer visualized for …

When cancer escapes the immune system, our defenses are rendered powerless and are unable to fight against the disease. Chimeric antigen receptor T cells (CAR T cells) re...

FDA approves treatment for patients with a type of…

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called no...

Boehringer Ingelheim announces FDA and EMA regulat…

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and E...

Selumetinib granted US Breakthrough Therapy Design…

AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) ha...

Novartis adds clinical and preclinical anti-inflam…

Novartis announced that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC fo...

Forxiga approved in Japan for type-1 diabetes

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T...

Novartis continues transformation into a leading m…

Novartis today completed the spin-off of the Alcon eye care devices business through a dividend-in-kind distribution to holders of Novartis shares and ADRs (American Depo...